Online first
Case report
Published online: 2024-06-18

open access

Page views 71
Article views/downloads 55
Get Citation

Connect on Social Media

Connect on Social Media

Multifocal ischaemic brain stroke as a clinical manifestation of the Trousseau syndrome in a patient with lung adenocarcinoma

Andrzej Paweł Felski1, Andrzej Kędracki1, Pola Altmajer1
DOI: 10.5603/mrj.99978

Abstract

Lung adenocarcinoma is the most common of all the histological lung cancer types, while Trousseau syndrome is the second leading cause of death — apart from the cancer itself — among affected people in this group. Based on the presented case and literature review, the authors discuss the current guidelines related to the diagnosis, as well as primary and secondary prevention of ischaemic stroke, and the treatment of acute stroke in cancer patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110(6): 1723–1729.
  2. Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022; 6(1): 307–320.
  3. Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007; 11(2): 89–96.
  4. Ikushima S, Ono R, Fukuda K, et al. Trousseau's syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016; 46(3): 204–208.
  5. Logothetis C, Pizanis C. Cerebral venous thrombosis in the setting of malignancy: case report and review of the literature. Case Reports in Hematology. 2020; 2020: 1–6.
  6. Woock M, Martinez-Majander N, Seiffge D, et al. Cancer and stroke: commonly encountered by clinicians, but little evidence to guide clinical approach. Ther Adv Neurol Disord. 2022; 15: 175628642211063.
  7. Savarapu P, Abdelazeem B, Isa S, et al. Cancer-Related non-bacterial thrombotic endocarditis presenting as acute ischemic stroke. Cureus. 2021; 13(5): e14953.
  8. Kwok G, Yau TCC, Chiu JW, et al. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016; 12(11): 2777–2789.
  9. Tota V, Dagonnier M, Wery D, et al. Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review. Lung Cancer. 2021; 160: 59–65.
  10. Zahir MN, Shaikh Q, Shabbir-Moosajee M, et al. Incidence of venous thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study. BMC Cancer. 2017; 17(1): 57.
  11. Alabiso I, Baratelli C, Brizzi MP, et al. Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed. Int J Clin Pharm. 2014; 36(6): 1141–1143.
  12. Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol. 2010; 55(12): 1237–1239.
  13. Sukegawa S, Kanno T, Kanai K, et al. Perioperative stroke in a patient undergoing surgery for oral cancer: A case report. Oncol Lett. 2016; 12(4): 2660–2663.
  14. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020; 51(10): 3156–3168.
  15. Cheng Y, Ning Y, Zhao Y, et al. Association between three-territory sign and prognosis of acute ischemic stroke patients with malignancy. Front Neurol. 2023; 14: 1265715.
  16. Selvik HA, Bjerkreim AT, Thomassen L, et al. When to screen ischaemic stroke patients for cancer. Cerebrovasc Dis. 2018; 45(1-2): 42–47.
  17. Jiang J, Shang X, Zhao J, et al. Score for predicting active cancer in patients with ischemic stroke: a retrospective study. Biomed Res Int. 2021; 2021: 5585206.
  18. Seystahl K, Gramatzki D, Wanner M, et al. A risk model for prediction of diagnosis of cancer after ischemic stroke. Sci Rep. 2023; 13(1): 111.
  19. Chen Y, Zhang C, Wang X, et al. Suitability of thrombolysis for patients with acute ischemic stroke complicated with Trousseau syndrome. Front Neurosci. 2020; 14: 481.
  20. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7): e364–e467.
  21. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5(4): 927–974.
  22. Rojas-Hernandez CM, Oo TH, García-Perdomo HA. Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017; 43(2): 233–240.
  23. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023; 41(16): 3063–3071.
  24. Hughes S, Szeki I, Nash MJ, et al. Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J. 2014; 7(5): 442–449.
  25. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
  26. Raskob G, Es Nv, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
  27. Agnelli G, Becattini C, Bauersachs R, et al. Caravaggio Study Investigators. Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with cancer: The Caravaggio Study. Thromb Haemost. 2018; 118(9): 1668–1678.
  28. Schrag D, Uno H, Rosovsky R, et al. CANVAS Investigators. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2023; 329(22): 1924–1933.
  29. Lin RJ, Green DL, Shah GL. Therapeutic anticoagulation in patients with primary brain tumors or secondary brain metastasis. Oncologist. 2018; 23(4): 468–473.
  30. Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015; 126(4): 494–499.